WHO grants EUL to CanSinoBIO’s Covid-19 vaccine
The World Health Organization (WHO) has granted an emergency use listing (EUL) for CanSino Biologics’ (CanSinoBIO) recombinant novel Covid-19 vaccine, Convidecia.
Given as a single-dose vaccination, Convidecia is a genetically engineered vaccine with the replication-defective adenovirus type 5 vector that expresses the spike S protein of the SARS-CoV-2 virus.
The latest decision is based on the totality of scientific data submitted by the company, including findings from a Phase III clinical trial analysing the safety and efficacy of the vaccine.
The move comes after the Strategic Advisory Group of Experts on Immunization (SAGE) of WHO analysed the vaccine and recommended the usage of single 0.5ml Convidecia dose in all people aged 18 years and above.
CanSinoBIO chairman and CEO Dr Xuefeng YU said: “We are pleased to have obtained the issuance of an Emergency Use Listing, as well as the usage recommendation from the Strategic Advisory Group of Experts on Immunization Committee and the Good Manufacturing Practices certificate.
“This EUL will greatly contribute to the expansion of vaccine access to underserved populations around the globe, representing a significant milestone for CanSinoBIO and further demonstrating our efforts in the pandemic fight.”
In April last year, the Instituto de Salud Pública de Chile (ISP) granted Emergency Use Authorization (EUA) to CanSinoBIO’s Convidecia.
May 20, 2022
